Every time Shubhangi publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...

Amjad Masad announced that Replit has raised $400 million in a series D, and also unveiled a powerful new agent.

Haya Odeh, Co-Founder and VP of Design for Replit, poses for a photo in San Francisco, Calif. on Sept. 30, 2024.

Amjad Masad’s Replit allows users to work together like they’re doodling on a white board. It also made him a billionaire along the way.

Quadratic regression is a classical machine learning technique to predict a single numeric value. Quadratic regression is an extension of basic linear regression. Quadratic regression can deal with ...

Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...

Strip the types and hotwire the HTML—and triple check your package security while you are at it. JavaScript in 2026 is just getting started. I am loath to inform you that the first month of 2026 has ...

This video breaks down the bizarre legal battle over who owns the JavaScript name. Despite not creating or maintaining the language, Oracle controls the trademark. The story traces how this happened ...

A critical vulnerability in the popular expr-eval JavaScript library, with over 800,000 weekly downloads on NPM, can be exploited to execute code remotely through maliciously crafted input. The ...

The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...